member of
- (CTR) Clinical and Translational Research Leader
- CTR: Leadership Team Leader
- CTR: SUNY Stroke Prevention Liaison to REACH
-
631-444-7692
Nachman, Sharon Professor
Positions
- Prof & Vice Dean Fac Affairs, Pediatrics - Infectious Disease, Stony Brook University
Research Areas
Affiliation
Publications
selected publications
-
article
- Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed Clinical Case Definitions for Classification of Intrathoracic Tuberculosis Disease. Consensus From an Expert Panel.. J Infect Dis. 205 Suppl 2:S199-S208. 2012
- High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial. 2012
- Human Immunodeficiency Virus Disease Severity, Psychiatric Symptoms, and Functional Outcomes in Perinatally Infected Youth. 2012
- Immunogenicity and Safety of 1 vs 2 Doses of Quadrivalent Meningococcal Conjugate Vaccine in Youth Infected with Human Immunodeficiency Virus. 2012
- Immunogenicity, Immunologic Memory, and Safety Following Measles Revaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy.. J Infect Dis. 206:512-522. 2012
- Longitudinal Study of Emerging Mental Health Concerns in Youth Perinatally Infected With HIV and Peer Comparisons. 2012
- Monitoring of HIV-1 DNA Load and Drug Resistance in Peripheral Blood Mononuclear Cells during Suppressive Antiretroviral Therapy does not Predict Virologic Failure. 2012
- Nevirapine-based therapy after suppression: can we switch? 2012
- Safety and Immunogenicity of 2009 Pandemic H1N1 Influenza Vaccination in Perinatally HIV-1-Infected Children, Adolescents, and Young Adults.. J Infect Dis. 206:421-430. 2012
- Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in 2- to 10-year-old Human Immunodeficiency Virus-infected Children. 2012
- Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. 2011
- Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. 2011
- Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. 2011
- Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. 2010
- CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. 2010
- Co-occuring psychiatric symptoms in children perinatally infected with HIV and peer comparison sample. 2010
- Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants.. J Infect Dis. 202:355-361. 2010
- Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. 2010
- Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. 2010
- Prevalence of pain and association with psychiatric symptom severity in perinatally HIV-infected children as compared to controls living in HIV-affected households. 2010
- Substance use and its association with psychiatric symptoms in perinatally HIV-infected and HIV-affected adolescents. 2010
- T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines. 2010
- The link between religion and HAART adherence in pediatric HIV patients. 2010
- A window into a public program for prevention of mother to child transmission of HIV: evidence from a prospective clinical trial. 2009
- Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.. J Infect Dis. 200:935-946. 2009
- Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. 2009
- Lyme disease: new thoughts and directions. 2009
- Mental health treatment patterns in perinatally HIV-infected youth and controls. 2009
- To treat or not to treat? No longer a question. 2009
- Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment. 2009
- Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. 2008
- Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. 2008
- Monosomy 1p36 uncovers a role for OX40 in survival of activated CD4+ T cells. 2008
- Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. 2008
- Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. 2008
- An evaluation of awareness: attitudes and beliefs of pregnant Nigerian women toward voluntary counseling and testing for HIV. 2007
- Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). 2007
- CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. 2007
- Genomic analysis of HIV type 1 strains derived from a mother and child pair of long-term nonprogressors. 2007
- Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. 2007
- A behavioral and cognitive profile of clinically stable HIV-infected children. 2006
- Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy.. J Infect Dis. 193:302-311. 2006
- Clinical and imaging study of human immunodeficiency virus-1-infected youth receiving highly active antiretroviral therapy: pilot study using magnetic resonance spectroscopy. 2006
- Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. 2006
- Incidence of opportunistic and other infections in HIV-infected children in the HAART era. 2006
- Moving beyond the clinic: nutritional intervention in a human immunodeficiency virus-infected pregnant population. 2006
- Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. 2006
- Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. 2005
- Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. 2005
- Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. 2005
- Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection.. J Infect Dis. 192:445-455. 2005
- Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. 2005
- Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children. 2005
- Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. 2005
- The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. 2005
- Use of complementary and alternative medicine by parents of children with HIV infection and asthma and well children. 2005
- Viral coinfection in the oral cavity of HIV-infected children: relation among HIV viral load, CD4+ T lymphocyte count and detection of EBV, CMV and HSV. 2005
- Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. 2004
- Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection. 2004
- Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. 2004
- Central nervous system Lyme disease. 2003
- Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. 2003
- Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. 2003
- [The association between oral manifestations and the socioeconomic and cultural characteristics of HIV-infected children in Brazil and in the United States of America]. 2003
- Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy. 2002
- How common is choosing to discontinue treatment for HIV? 2002
- Mother-to-child transmission in the United States of subtypes D and A/G human immunodeficiency virus type 1. 2002
- Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. 2002
- Overdiagnosis and overtreatment of Lyme disease in children. 2002
- Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. 2002
- Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children. 2002
- Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. 2002
- Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).. J Infect Dis. 183:1732-1738. 2001
- Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. 2001
- Single-dose doxycycline for the prevention of Lyme disease. 2001
- Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. 2000
- Group-specific antibody levels surrounding invasive pneumococcal illness in children infected with human immunodeficiency virus.. J Infect Dis. 181:1817-1821. 2000
- Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children.. J Infect Dis. 182:96-103. 2000
- Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. 2000
- Pneumocystis carinii pneumonia in adolescents. 2000
- Varicella zoster infection in HIV-infected children. 2000
- CCR5 genotype and resistance to vertical transmission of HIV-1. 1999
- Management of the infant born to an HIV-1 infected mother. 1999
- Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. 1999
- Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group. 1999
- Implications and management of oral diseases in children and adolescents with HIV infection. 1997
- Maternal serum vitamin A levels are not associated with mother-to-child transmission of HIV-1 in the United States. 1997
- Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: A 3-year follow-up. 1997
- Catheter-associated fungemia due to Wangiella (Exophiala) dermatitidis. 1996
- Proteolysis of insulin-like growth factor-binding protein-3 in human immunodeficiency virus-positive children who fail to thrive. 1996
- Testing cord blood human chorionic gonadotropin as a surrogate marker for early identification of human immunodeficiency virus-1 infection in children. 1996
- Tuberculin skin testing in a pediatric population exposed to human immunodeficiency virus. 1996
- Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission.. Proc Natl Acad Sci U S A. 92:12100-12104. 1995
- Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. 1995
- High failure rate of dapsone and pentamidine as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected children. 1994
- Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load.. Proc Natl Acad Sci U S A. 91:8037-8041. 1994
- Thyroid function in children with perinatally acquired antibodies to human immunodeficiency virus. 1994
- Cholestatic hepatitis in children infected with the human immunodeficiency virus. 1993
- Hairy leukoplakia in a child with AIDS--a rare symptom: case report. 1993
- Liver abscess caused by Clostridium bifermentans following blunt abdominal trauma. 1989
- Second or recurrent diaphragmatic hernia associated with Haemophilus influenzae pneumonia and sepsis. 1989
Research
research overview
- Dr. Nachman has led the Division of Pediatric Infectious Diseases at Stony Brook University Medical Center since 1992. She serves as Principal Investigator of numerous private pharmaceutical clinical research protocols and heads the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) initiative funded by the National Institutes of Child Health and Development (NICHD) at Stony Brook, as well as other National Institutes of Health (NIH) initiatives. In addition, she is the Director of the Office of Clinical Trials and the Associate Dean of Scientific Affairs.Dr. Nachman has published extensively on antibiotics and vaccines as well as maternal and pediatric HIV clinical research and is a nationally and internationally renowned speaker. She is a member of the National Medical Honor Society, received the Distinguished Alumni Award from SUNY Stony Brook in 1997 and has been honored by the Department of Pediatrics for Excellence in Teaching in 2001 and 2002.
Contact
name suffix
- FAAP
- MD
fax
- 631-444-7292